三、主要科研工作与成绩 近5年主持或参加的科研项目： 1）国家自然科学基金委员会, 面上项目, 82373226, ALYREF靶向PD-L1mRNA的m5C甲基化修饰介导NSCLC免疫逃逸分子机制研究, 2024-01-01 至 2027-12-31, 48万元, 在研, 主持 2）国家自然科学基金委员会, 面上项目, 82072564, 糖酵解通过肿瘤微环境促进肺腺癌EGFR-TKI耐药的机制研究, 2021-01-01 至 2024-12-31, 55万元, 在研, 参与 3）上海市科学技术委员会, 实验动物研究领域计划项目, 19140902600, 肺源性肝转移癌的肝脏原位PDX模型构建与研究, 2019-05 至 2022-04, 30万元, 结题, 主持 4）上海交通大学医学院附属胸科医院, 基础研究培育项目, 2019YNJCM06, CD47高表达细胞外囊泡免疫调节肝脏巨噬细胞促进非小细胞肺癌肝转移的作用机制研究, 2020-01 至 2021-12, 20万元, 结题, 主持 5）上海交通大学医学院附属胸科医院, 协同创新项目, YJXT20190210, 基于大数据背景下肺部结节影像学诊断人工智能检测模型的研究与应用, 2019-01 至 2021-12, 50万元, 结题, 主持
发表文章和论著：
Xingtong Zhang; Saifeng Fang; Yongchun Jin; Ying Huang; Shucheng Wang; Jie Wang*; Yunhua Xu*; Comprehensive performance evaluation of valuable medical equipment based on cloud modelling and combined weighting methodologies, Eng. Appl. Artif. Intell, 2025;154:110969（通讯作者，IF 7.5，1区） Yiran Yang#; Leiqun Cao#; Xin Xu#; Dan Li; Yiran Deng; Lan Li; Bingjie Zeng; Haixia Jiang; Liang Shan; Yiwen Huang; Yunhua Xu*; Lifang Ma*; NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer, Cancer Immunol Immun, 2025, 74(4): 132. Su X, Liang F, Zeng Y, Yang ZR, Deng YZ, Xu YH*, Cai XW. Radiation-Induced Endothelial Ferroptosis Accelerates Atherosclerosis via the DDHD2-Mediated Nrf2/GPX4 Pathway. Biomolecules. 2024 Jul 22;14(7):879. doi: 10.3390/biom14070879.（并列通讯作者，IF 4.8，2区） Xu Y#、*, Gu L, Zhu L, Miao Y, Cui X.A novel anti-CD47 protein antibody and toll-like receptor agonist complex detects tumor surface CD-47 changes in early stage lung cancer by in vivo imaging. International journal of biological macromolecules.2024 Jun 20;274(Pt 1):133322. doi: 10.1016/j.ijbiomac.2024.133322. （第一兼通讯，IF 7.7，1区） Yang Y#, Liu Z#, Jiang C, Pan J, Yu B, Zhu K, Xu Y*, Li Z*. Prognostic Value of Combination of Lymphocyte-to-Monocyte-Ratio and CYFRA 21-1 in Esophageal Squamous Cell Carcinoma. World J Surg. 2023 Oct 4. doi: 10.1007/s00268-023-07190-3. Epub ahead of print. PMID: 37792039. （并列通讯作者，IF 2.6，2区） Zhao R#, Xu Y#, Chen Y#, Zhang J#, Teng F, Liao S, Chen S, Wu Q, Xiang C, Pang J, Shang Z, Zhao J, Bao H, Bao H, Shao Y, Lu S*, Han Y*. Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma. NPJ Precis Oncol. 2023 Aug 26;7(1):80. doi: 10.1038/s41698-023-00430-8. PMID: 37634047; PMCID: PMC10460394. （并列第一作者，IF 7.9，1区） Xu X#, Cui J#, Wang H#, Ma L#, Zhang X, Guo W, Xue X, Wang Y, Qiu S, Tian X, Miao Y, Wu M, Yu Y, Xu Y*, Wang J*, Qiao Y*. IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. Mater Today Bio. 2022 Nov 24;17:100503. doi: 10.1016/j.mtbio.2022.100503. PMID: 36457846; PMCID: PMC9707255. （并列通讯作者，IF 8.2，1区） Xu Y#, Gu L#, Li Y, Zhao R, Jian H, Xie W, Liu L, Wu H, Ren F, Han Y*, Lu S*. Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models. Front Oncol. 2022 Oct 21;12:1024818. doi: 10.3389/fonc.2022.1024818. PMID: 36338758; PMCID: PMC9634635.（第一作者，IF 4.7，2区） Zhang X#, Xu Y#, Ma L#, Yu K, Niu Y, Xu X, Shi Y, Guo S, Xue X, Wang Y, Qiu S, Cui J, Wang H, Tian X, Miao Y, Meng F, Qiao Y*, Yu Y*, Wang J*. Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma. Cancer Commun (Lond). 2022 Apr;42(4):287-313. doi: 10.1002/cac2.12275. Epub 2022 Feb 20. PMID: 35184419; PMCID: PMC9017758. （共同第一作者，影响因子 16.2，1区） Wang X#, Sun Y#, Xu Y#, Wen D, An N, Leng X, Fu G, Lu S*, Chen Z*. Mini-patient-derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non-small cell lung cancer. Cell Biol Int. 2021 Sep;45(9):1887-1896. doi: 10.1002/cbin.11622. Epub 2021 Jun 26. PMID: 33945662. （共同第一作者，影响因子 3.612，3区） Xu Y#、*, Fu J#, Cao W#, Zhu L, Jin Y, Yin Q, Ye J, Zhou H*. Efficacy and safety of a new disposable percutaneous positioning device invented to facilitate the precision of percutaneous core needle lung biopsies: a prospective, open and randomized controlled study. J Thorac Dis. 2021 Aug;13(8):4965-4976. doi: 10.21037/jtd-20-3282. PMID: 34527335; PMCID: PMC8411179. （第一作者，影响因子2.895，3区） Xu Y#, Fang W#, Cheng B, Chen S, Gu L, Zhu L, Pan Y*, Zhou Z*. Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone. J Thorac Dis. 2020 May;12(5):2499-2506.（第一作者，影响因子2.046，3区） Yunhua Xu#, Yan Pan#, Zhen Zhou*. Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. J Thorac Dis. 2019 Nov;11(11):4671-4681. doi: 10.21037/jtd.2019.10.58. PMID: 31903256; PMCID: PMC6940230.（第一作者，影响因子2.027） Qiao-mei Guo#, Lin Wang#, Wen-jun Yu, Li-hua Qiao, Ming-na Zhao, Xiao-meng Hu, Ya-meng Sun, Sheng Ni, Yun-hua Xu*, Jia-tao Lou*. Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay. J Cancer. 2019, 10(18): 4341-4349.（共同通讯作者，影响因子3.182） Xu Y#, Song X, Du F, Zhao Q, Liu L, Ma Z, Lu S*. A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. J Cancer. 2018, 9(24):4718-4725. （第一作者，影响因子3.249分） Xu Y#, Zhang F#, Pan X, Wang G, Zhu L, Zhang J, Wen D*, Lu S*. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. Cancer Commun (Lond). 2018 May 9;38(1):19. （第一作者，影响因子3.82分） Gu L#, Xu Y #, Chen Z, Pan Y, Lu S*. Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. Biomed Pharmacother. 2015 Dec;76:134-140. （Co-First Author）（共同第一作者，影响因子2.02分） Xu Y#, Lu S*. Regulation of β-catenin-mediated esophageal cancer growth and invasion by miR-214. Am J Transl Res. 2015 Nov 15; 7(11):2316-2325. （第一作者，影响因子3.146分） Xu Y#, Lu S*. Role of WNT1-inducible-signaling pathway protein 1 in etoposide resistance in lung adenocarcinoma A549 cells. Int J Clin Exp Med 2015;8(9):14962-14968. （第一作者，影响因子1.227分） Zhang X#, Xu Y#, He C#, Guo X, Zhang J, He C, Zhang L, Kong M, Chen B*, Zhu C*. Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2015 Jun;111(7):834-839. （Co-First Author）（共同第一作者，影响因子3.224分） Xu Y#, Lu S*. Transforming growth factor β1 induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non small cell lung cancer cell line. Mol Med Rep. 2015 Jan;11(1):417-421. （第一作者，影响因子1.554分） Xu Y#, Pan Q#, Wang C#, He C, Su Z, Guo X, Zhang J, Kong M, Ke S, Zhang J, Chen B, Sheng H*, Zhang X*. Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors. Am J Cancer Res. 2014 Nov 19; 4(6):934-942. （第一作者，影响因子4.165分） Xu Y#, Lu S*. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol. 2014 Mar; 40(3):311-317. （第一作者，影响因子2.614分） Xu Y#, Lu S*. Metformin inhibits esophagus cancer proliferation through upregulation of USP7. Cell Physiol Biochem. 2013; 32(5):1178-1186. （第一作者，影响因子3.415分）
发明专利
1）一种纳米抗压抗潮防护服, 2022-1-25, 中国, ZL202120836355.X (专利) （排名第一） 2）一种接种液组合物及利用其构建恶性胸腔积液来源异种移植瘤动物模型的方法, 2020-4-7, 中国, 201611012480.9 (专利) （排名第三） 3）一种穿刺用定位装置, 2019-8-20, 中国, 201821638194.8 (专利) （排名第二） |
